Methaqualone is banned in the United States because rampant recreational abuse, a high overdose risk, life-threatening withdrawal, and severe dependence made the drug’s harms indefensible once safer sleep medications reached the market. Sold in the 1960s and 1970s under brand names like Quaalude and Sopor, it moved through progressively tighter federal drug schedules before landing in Schedule I in 1984, where it can no longer be prescribed for any purpose.
An Abuse Epidemic the FDA Didn’t See Coming
Methaqualone was first synthesized in India in 1951 during antimalarial research. Its sedative and muscle-relaxant effects were noticed quickly, and by the early 1960s drug companies were selling it for insomnia and anxiety as a supposedly safer alternative to barbiturates. The FDA approved it for prescription use in 1965 and placed it in Schedule V of the Controlled Substances Act, a classification with almost no restrictions on how doctors could prescribe.
That light-touch approach collapsed within a few years. At prescribed doses of 150 to 300 mg the drug produced relaxation, drowsiness, and mild euphoria, and the euphoria was exactly what made it a runaway recreational hit. By the late 1960s Quaaludes had moved from medicine cabinets into party scenes, and the reputation as a “safe” pharmaceutical made users cavalier about the doses they were taking. The DEA estimated that 20 million pills were circulating on the street by 1980, with projections that the figure would double within a year.
Users routinely mixed methaqualone with alcohol. Both substances suppress the central nervous system through overlapping pathways, and the combined effect on breathing exceeded what either produced alone. Impaired coordination and judgment under the drug were also tied to fatal car crashes, layering a traffic-safety crisis on top of the overdose one.
Overdose and Withdrawal Were Both Deadly
The lethal dose of methaqualone by itself runs roughly 3 to 8 grams, but co-ingestion with alcohol could induce coma at far lower amounts. Tolerance built fast. Some heavy users escalated to 2,000 mg per day to keep feeling effects, closing the gap between a recreational dose and a fatal one.
Overdose progressed from deep sedation to respiratory failure, coma, and death. Severe cases sometimes required hemoperfusion, a procedure that filters the drug from the blood over many hours; one documented patient in deep coma after ingesting more than 4.5 grams needed 10 hours of continuous filtration before becoming responsive.
Stopping the drug was dangerous too. Methaqualone belongs to the sedative-hypnotic class, and abrupt cessation after heavy use could trigger seizures, delirium, and hallucinations. Safe detox required hospital supervision with high doses of intravenous benzodiazepines or barbiturates, and severe cases needed intensive care monitoring of heart rhythm, breathing, temperature, and fluid balance. Heavy drinkers faced cross-tolerance between alcohol and methaqualone, meaning they needed larger doses to feel anything and pushed themselves closer to overdose with each use.
Safer Sleep Drugs Erased the Medical Case
A drug this dangerous might still have kept a place in medicine if nothing else worked. Something else did. Benzodiazepines like diazepam had already begun displacing older sedatives by the 1970s, and by the 1980s the nonbenzodiazepine “Z-drugs” such as zolpidem offered a more targeted approach. Methaqualone and barbiturates blanketed the entire central nervous system; zolpidem selectively targets specific GABA receptor subtypes involved in sleep, producing strong sedation without the pronounced muscle relaxation, euphoria, or anticonvulsant effects that drove abuse of the older compounds.
That selectivity matters clinically. Zolpidem carries a lower potential for tolerance and dependence than either benzodiazepines or methaqualone, and it doesn’t attract substance abusers the way Quaaludes did. One review described the older sedatives, methaqualone included, as having a “significant toxicity profile.” Once safer options existed, there was no medical justification for keeping methaqualone available.
The Scheduling Timeline
The ban unfolded in stages as evidence of harm outpaced the initial regulatory response.
Internationally, methaqualone was placed in Schedule II of the 1971 United Nations Convention on Psychotropic Substances, a treaty designed to restrict psychoactive drugs to medical and scientific use. That signaled growing concern but still permitted controlled prescribing.
In the U.S., the drug started in 1965 at Schedule V, with essentially no restrictions on clinical use beyond the prescription requirement. As abuse escalated, the DEA moved it to Schedule II in October 1973, acknowledging its high potential for abuse and severe dependence risk. Schedule II still allowed prescriptions but imposed manufacturing quotas and tighter dispensing controls. Domestic pharmaceutical production ceased by 1983. In 1984, methaqualone was reclassified to Schedule I, the most restrictive category, meaning it could no longer be prescribed for any purpose.
How the DEA Cut Off the Supply
The final blow wasn’t street-level enforcement. Gene Haislip, then the DEA’s third-ranking official, led an effort to pressure pharmaceutical chemical suppliers in West Germany, Austria, Hungary, and China to stop exporting the raw powder and precursors used to make methaqualone. Cutting off supply at the source accomplished what arrests hadn’t, and by 1984 Quaaludes had largely vanished from the American market.
What Schedule I Means Legally Now
Methaqualone remains a Schedule I controlled substance under 21 U.S.C. § 812. The federal government treats it as having a high potential for abuse, no accepted medical use, and no accepted safety for use even under medical supervision. Possessing, manufacturing, or distributing it is a federal crime.
Simple Possession
Under 21 U.S.C. § 844, possessing methaqualone without a valid prescription carries escalating penalties based on prior convictions:
- First offense: up to one year in prison and a minimum $1,000 fine.
- Second offense with one prior drug conviction: 15 days to two years in prison and a minimum $2,500 fine.
- Third or subsequent offense: 90 days to three years in prison and a minimum $5,000 fine.
Courts cannot suspend or defer these minimum sentences.
Manufacturing or Distribution
Under 21 U.S.C. § 841, distributing a Schedule I substance carries up to 20 years in prison and fines up to $1 million for an individual on a first offense. If someone dies or suffers serious bodily injury from the drug, the sentence rises to a mandatory minimum of 20 years and can reach life imprisonment. A second distribution conviction after a prior felony drug offense doubles the maximum to 30 years and the fine ceiling to $2 million.
Asset Forfeiture
Under 21 U.S.C. § 881, any controlled substance possessed illegally is forfeited automatically, along with cash, vehicles, and other assets used to facilitate the violation or traceable to drug proceeds. The government’s ownership interest in forfeitable property vests at the moment the offense is committed, not at the time of seizure.
Still a Problem Outside the U.S.
The ban worked domestically but not globally. South Africa is the world’s largest illegal market for methaqualone, where it’s sold as Mandrax and commonly smoked with cannabis in a combination called “white pipe.” It ranks as the country’s second most commonly used illicit drug, and law enforcement estimates that most of the supply is imported, primarily from manufacturers in China and India. The persistence of the drug in southern Africa is a reminder of why the American ban only stuck once the DEA reached upstream to the chemical suppliers themselves.